Q-omics provides the consensus-scored RIPK3 profile across patient tissues and cancer cell-line models. RIPK3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, RIPK3 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, RIPK3 protein abundance shows 19,678 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LGG, KICH, and LSCC as cancer lineages where RIPK3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RIPK3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RIPK3 survival associations across molecular data types. RIPK3 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RIPK3 RNA expression–survival associations across cancer types. High RIPK3 expression shows unfavorable associations in LGG, but favorable associations in MESO, SARC, UCEC, COAD and BRCA. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for RIPK3 RNA expression.
This table summarizes RIPK3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in KICH for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for RIPK3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RIPK3 shows lower tumor expression in KICH, LUSC, KIRP, COAD and READ and higher tumor expression in CHOL. The KICH box plot shows higher RIPK3 RNA expression in normal versus tumor tissue (log2 FC = −1.588, t-test p < 0.001).
This table shows molecular features associated with RIPK3 in patient tissues and cancer cell lines. In patient samples, RIPK3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, RIPK3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and STOMACH.
